TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Decision to intervene
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sputum Induction Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in nasal symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One-time intubation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from recurrence of VT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Biological Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Activities-Specific Balance Confidence Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in Falls Efficacy Scale - International
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in Berg Balance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Vital Sign Values of Potential Clinical Importance (PCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve infinity (AUCinfinity) for rifampin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (Cmax) of rifampin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance (CL) of rifampin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of distribution at steady state (Vss) of rifampin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Attitudes About HPV Vaccine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants That Are DSA Positive
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Alive and Free of Respiratory Failure at Day 28
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Patients Who Complete the Pre/Post Exercise Intervention Testing
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Log number of In Vitro T cells depletion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of grade II-IV acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Time to next asthma or COPD exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mechanical visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leprosy incidence
Endpoint domain: Mortality/survival
Primary endpoint: Plasma levels of isoniazid, rifampicin, pyrazinamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HVPG from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalized neuromuscular activity (EMG) of the quadriceps and hamstring muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean Change in Average Daytime Ambulatory Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total sperm motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sperm morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average functional hearing gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End of Treatment Response Rate at Week 72 in Genotype 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: End of Treatment Response in Genotype 2 and 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sustained Viral Response (SVR) Rates in CHC Genotype 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: SVR Rates in Genotype 2 and 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change of Pain Over 26 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamstrings Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Total Score of Investigator's Symptomatic Severity Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time for positioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attenuation of inflammatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Severe toxicity (Grade 3-5)
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of the ShangRIng device for circumcision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety of the ShangRIng device for circumcision
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in number of smoked cigarettes/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident cases of breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumor Stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnosis of autoimmune disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of IM intervention on chronic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in ARFI-elastography value for spleen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-epidermal Nerve Fiber Density (IENFD) Fibers Per mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Score on the Expanded Disability Status Scale (EDSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trajectories of physical activity and the relationship to obesity risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Meeting the Primary Outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Readiness for appropriate change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of the Women's Health CoOp (WHC) intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adoption of the Women's Health CoOp (WHC) intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain Score After Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of successful Follow Me movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intracranial progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of Drinking Days in the Past Two Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Drinks Consumed Per Two Week Segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Heavy Drinking Days Per Two Week Segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Brain Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total difficulties score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: number of subjects with AEs, DLTs, abnormal clinical laboratory values or physical exam results
Endpoint domain: Adverse events/effects
Primary endpoint: antitumor activity assessed by objective response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: antitumor activity assessed by disease control rate (DCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serum concentration of 24,25-dihyroxyvitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bioimpedance analysis trend during dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of ischemic stroke imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of bronchiectatic patients with pseudomonal infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Plasma concentrations of GSK961081 and fluticasone propionate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Derived pharmacokinetic parameters of GSK961081 and fluticasone propionate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of intra-abdominal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neural electrophysiological test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: clinical efficacy of ertumaxomab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Visual Analogue Scale (VAS) of Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric Rating Scale (NRS) of Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: McGill Pain Questionnaire (MPQ) of Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titer(s) of Poliovirus Types 1, 2, and 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMT of Serum Anti-rotavirus Immunoglobulin A (IgA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunogenicity of RotaTeq™ as Measured by Serum Neutralizing Antibody Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Estimated Intraoperative Blood Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: migration/rotation of prosthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assess adverse events (per CTCAE v4.0 criteria)
Endpoint domain: Adverse events/effects
Primary endpoint: Development of glaucoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Toronto Western Spasmodic Rating Scale (TWSTRS) Movement Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients where acquisition of a comprehensive raw CEST dataset can be performed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with quantitative maps of different CEST contrasts produced
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signal-to-noise ratio on the CEST contrasts determined
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with dose-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Relative changes on biochemical markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal tolerable dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recommended phase II dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of recovery after cesarean section
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall Improvement in Periorbital Wrinkles and Rhytids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: International prostate symptoms score (IPSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Wake in Central Aortic Pulse Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Cerebral Vascular Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Peak Reactive Hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of immunosuppression biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pathologically aggregated α-synuclein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Scores in the Young Mania Rating Scale (BD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores in the SNAP-IV (ADHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: toleration
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of AF recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Contrast induced acute kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Development of surgical skill
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cmax of single-dose rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tmax of single-dose rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of single-dose rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ of single-dose rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t½ of single-dose rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quality of Life in Epilepsy - 31 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time until pathogen identification through MCC-IMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time until pathogen identification through conventional microbiological diagnostic methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Enteric Bacterial Contamination on the Exposed Surface of the CleanCision Sheath
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serious Adverse Events Directly Attributable to the Device
Endpoint domain: Adverse events/effects
Primary endpoint: Systolic arterial pressure response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic arterial pressure response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ventilator Associated Condition (VAC)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of T cells expressing PD-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient agreement on health improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of colonized infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bacterial colonization levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Metamemory evaluation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total surgical time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative vitreous hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from baseline of severity of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of functional status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Binding of [F-18]FBR at peripheral benzodiazepine receptor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postoperative Excess Weight Loss (EWL) %
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence and incidence of hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence and incidence of renal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fugl-Meyer Upper Limb Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Dysphoric Apathy/Retardation Sub-factor (MDAR)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Geometric mean antibody titres to influenza H9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients with a PFS2 to PFS1 ratio superior to 1.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of Zoledronic Acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug concentrations of theophylline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Nocturnal Hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of intracerebral administration of NSCs
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of intracerebral administration of NSCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients With Obstruction Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Titres of RSV-A Neutralizing Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ratio of 18F-GP1 standardized uptake values in thrombus vs blood pool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of chronic neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to first occurrence of composite cardiovascular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Accelerometer-based Kinesia Kinetic Tremor Combined Score at Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Randomization in Accelerometer-based Kinesia Kinetic Tremor Combined Score at Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in the Accelerometer-based Kinesia Upper Limb Tremor Combined Score at Day 15
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Moderate to Vigorous Physical Activity (MVPA)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to Complete Wound Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Knee Osteoarthritis Outcome Score (KOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Completion of Planned Oncologic Therapy Without Cardiac Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of subjects achieving clinically relevant steroid-free remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Adolescent Use of Marijuana
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ability to Limit Substance Use
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prevention of nosocomial S. aureus sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Frequencies of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: sensitivity/specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrist flexion torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in serum levels of cytokines and trophic factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Right ventricular systolic and diastolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Biventricular myocardial fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Phosphorylation of structural myocardial proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean QOL Change From Baseline at Each Follow-up Assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall Longitudinal Change in QOL From Baseline
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: NIHSS score at admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mRS on 90 day
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Recovery times of eyelash reflex and eye opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to going home
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status